SYK and systemic mastocytosis: SYK has previously been shown to be a target of midostaurin and its metabolites, CGP52421 and CGP62221, in advanced systemic mastocytosis, a hematopoietic neoplasm characterized by expansion and abnormal accumulation of mast cells [25].